60 Degrees Pharmaceuticals (SXTP) announced that the first patient has been enrolled in NCT06478641, an expanded access clinical study intended to confirm the activity of tafenoquine in treating patients with persistent babesiosis who have failed standard of care treatment and are at high risk of experiencing a relapse. “The promise shown by tafenoquine in treating relapsing babesiosis can certainly give patients and physicians reason for hope and optimism,” said Geoff Dow, PhD, chief executive officer of 60 Degrees Pharmaceuticals. “The Tafenoquine for Babesiosis Expanded Access clinical study may strengthen that hope in a patient population that has few treatment options today. We are pleased to be leading the way in supporting that effort.”
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SXTP:
- 60 Degrees signs patent license deal with Tufts Medical, says H.C. Wainwright
- 60 Degrees, Tufts Medical Center announces patent license agreement
- 60 Degrees expands tafenoquine clinical trial to Brigham and Women’s Hospital
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
